Last reviewed · How we verify
TETULOMAB TETRAXETAN LU-177
At a glance
| Generic name | TETULOMAB TETRAXETAN LU-177 |
|---|---|
| Modality | Monoclonal antibody |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anaemia
- Lymphocyte count decreased
- Diarrhoea
- Nausea
- Dysphagia
- Fatigue
- Oral candidiasis
- Neutrophil count decreased
- Blood lactate dehydrogenase increased
- White blood cell count decreased
- Platelet count decreased
- Blood calcium increased
Key clinical trials
- Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) (PHASE1)
- Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TETULOMAB TETRAXETAN LU-177 CI brief — competitive landscape report
- TETULOMAB TETRAXETAN LU-177 updates RSS · CI watch RSS